Donepezil - Eisai

Drug Profile

Donepezil - Eisai

Alternative Names: Aricept; Aricept D; Aricept Dry Syrup; Aricept Evess; Aricept ODT; Aricept SR; Donepezil hydrochloride; Donepezil SR; E 2020; E 2022; Eranz

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ICURE; Pfizer; Teikoku Pharma USA
  • Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Lewy body disease; Vascular dementia
  • Phase III Down syndrome
  • No development reported Attention deficit and disruptive behaviour disorders; Migraine
  • Discontinued Aphasia; Attention-deficit hyperactivity disorder; Dementia; Mild cognitive impairment

Most Recent Events

  • 27 Nov 2017 Yokohama City University and Eisai completes a clinical trial for Lewy body disease in Japan (UMIN000018889)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Japan (Transdermal, Patch)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Japan (Transdermal, Tape)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top